News
Get it by emailWhat has changed, and when. We add a story here when a test finishes, a rule changes, or a warning goes out. We skip the hype. Newest first.
Feb 2025
Cheap copies of Wegovy are shut down
For a while there was not enough Wegovy to go around. During a shortage, other pharmacies are allowed to make their own copies. Health officials said the shortage was over in February 2025. So those copies had to stop. The same thing happened with Zepbound two months earlier.
Dec 2024
A new combo drug loses 22.7 percent, and the stock still drops
CagriSema puts two drugs in one pen. In its big test, people lost about 22.7 percent of their weight. That is a lot. But investors had guessed 25 percent. So the company's stock fell. This is a good lesson. A number can be great for patients and still disappoint Wall Street.
Dec 2024
Zepbound is approved for sleep apnea
Sleep apnea is when you stop breathing for short moments while you sleep. It can make you tired all day. This was the first time one of these drugs was approved for a different problem, not just for weight. It matters because insurance is more likely to pay when a drug treats a named illness.
Feb 2024
A test finally shows what happens when you stop
Everyone takes the drug for a while. Then half get switched to a fake shot without knowing. The ones on the fake shot started gaining the weight back. The ones who kept taking the real drug kept losing. This is the clearest proof that the drug holds the weight down. It does not fix anything for good.
Nov 2023
Big test finds 20 percent fewer heart attacks and strokes
More than 17,000 people took part. All of them had heart disease already. None had diabetes. The people on Wegovy had about 20 percent fewer heart attacks and strokes than the people on the fake shot. This changed how doctors talk about these drugs. It stopped being only about weight.
Nov 2023
Zepbound goes on sale for weight loss
The same drug had already been sold for diabetes since 2022, under the name Mounjaro. Now it got a second name and a second use. It was the first drug of its kind, copying two gut messages instead of one, that you could get for weight.
Jun 2023
An early test of a stronger shot hits 24 percent
Retatrutide copies three gut messages. In a mid-stage test, people lost about 24 percent of their weight in under a year. Here is the part that got attention. People were still losing weight when the test ended. So nobody knows where it stops. Bigger tests are running now.
2023 and after
Warnings about fake and copied versions
Health officials found that some copies sold online were not the same drug at all. They used a different form of the ingredient. Officials also got reports of people taking far too much by mistake. The vials and syringes were confusing. Some people ended up in the hospital.
Apr 2022
People who stopped gained back two thirds
This study followed people for a year after they stopped taking Wegovy. On average they gained back about two thirds of what they had lost. Their blood pressure and blood sugar drifted back too. Most news stories about these drugs leave this part out.
Jun 2022
The test that started it all: 21 percent
This was the first time a drug of this kind reached about 21 percent weight loss. It was roughly double what the older drugs did. Every newer drug since then gets compared to this number.
Nothing in that group yet. Try another button.
About the dates
The date is when the news came out, not when the test started. Tests often run for years before anyone hears the results.